Spero Therapeutics, Inc.
SPRO
$2.38
-$0.05-2.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 141.56% | -60.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 141.56% | -60.95% | |||
| Cost of Revenue | -21.56% | -85.29% | |||
| Gross Profit | 145.49% | 87.61% | |||
| SG&A Expenses | -13.86% | -3.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.99% | -43.08% | |||
| Operating Income | 83.78% | 30.18% | |||
| Income Before Tax | 87.74% | 32.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 87.74% | 33.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 87.74% | 33.62% | |||
| EBIT | 83.78% | 30.18% | |||
| EBITDA | 83.78% | 30.18% | |||
| EPS Basic | 87.90% | 34.62% | |||
| Normalized Basic EPS | 88.35% | 31.64% | |||
| EPS Diluted | 87.90% | 34.81% | |||
| Normalized Diluted EPS | 88.35% | 31.64% | |||
| Average Basic Shares Outstanding | 1.17% | 1.54% | |||
| Average Diluted Shares Outstanding | 1.17% | 1.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||